AXL and neoplasm: Boshuizen et al. showed that an antibody–drug conjugate targeting AXL called enapotamab vedotin (EnaV) not only has direct tumor killing, but also induces inflammation and ICD of tumor cells in melanoma and lung cancer models (165).